Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia

We hypothesized that GTI-2040, a 20-mer oligonucleotide complementary to the R2 subunit mRNA of ribonucleotide reductase, combined with high dose cytarabine (HiDAC) would result in enhanced cytotoxicity by favoring Ara-CTP DNA incorporation. In a phase I dose escalation trial, adults (≥60 years) wit...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Leuk Lymphoma
Main Authors: Klisovic, Rebecca B., Blum, William, Liu, Zhongfa, Xie, Zhiliang, Kefauver, Cheryl, Huynh, Lenguyen, Zwiebel, James A., Devine, Steven M., Byrd, John C., Grever, Michael R., Chan, Kenneth K., Marcucci, Guido
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4298748/
https://ncbi.nlm.nih.gov/pubmed/24015841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2013.838764
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares